- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | CURASIGHT: Major Shareholding Notification - ownership restructuring - related party transaction | 1 | Cision News | ||
| 27.08. | Curasight publishes Interim Report Q2 2026 | 2 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 27.07. | Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma) | 1 | Cision News | ||
| 22.06. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | 2 | Cision News | ||
| 22.06. | Curasight A/S announces its intention to carry out a directed issue of shares | 1 | Cision News | ||
| 08.06. | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma) | 523 | PR Newswire | COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial... ► Artikel lesen | |
| 28.05. | CURASIGHT: Interim report Q1 2026 | 2 | Cision News | ||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 366 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 556 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 437 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 1.230 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 1.027 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 471 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 24,630 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| SURROZEN | 33,630 | -0,15 % | H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation | ||
| KYMERA THERAPEUTICS | 115,81 | 0,00 % | Kymera Therapeutics auf Stifel-Forum: Schnellerer Entwicklungspfad für führenden Wirkstoffkandidaten | ||
| CG ONCOLOGY | 68,76 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,160 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| AMYLYX PHARMACEUTICALS | 30,140 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| ABSCI | 10,345 | 0,00 % | Anlegervertrauen zerstört: 80 Millionen Betroffene: Novo greift nach dem Milliardenmarkt Haarausfall | © Foto: Frank Hoermann / SVEN SIMON - SVEN SIMONNovo Nordisk sucht Wachstum jenseits von Wegovy - und nimmt jetzt einen überraschenden Milliardenmarkt mit 80 Millionen Betroffenen allein in den USA... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,885 | -0,13 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| ERASCA | 14,520 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,380 | 0,00 % | Citizens reiterates Summit Therapeutics stock rating on trial data | ||
| MINERALYS THERAPEUTICS | 26,590 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum | ||
| IMMUNOME | 22,300 | -0,18 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| PRAXIS PRECISION MEDICINES | 282,19 | +0,14 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| PROTAGONIST THERAPEUTICS | 137,31 | 0,00 % | Protagonist Therapeutics Announces $300 Million Share Repurchase Program | NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the... ► Artikel lesen | |
| APIMEDS PHARMACEUTICALS US | 5,050 | +0,40 % | Morning Market Movers: Apimeds Pharmaceuticals US, Akamai Technologies, Greenland Energy, Legacy Education See Big Swings | BEIJING (dpa-AFX) - At 6:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
CURASIGHT A/S gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,250 Euro und damit +3,73 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.